Drug intelligence / Profile preview

DMR-003

Development stage: Unknown
Lead developer: Damora Therapeutics

Overview

**DMR-003** is a preclinical-stage therapeutic candidate developed by Damora Therapeutics for unmet medical needs. Limited public information is available on its specific mechanism of action, primary indications, or clinical profile, with the highest reported R&D status being preclinical. The program is part of Damora's pipeline, which includes related candidates like DMR-001 and DMR-002, potentially leveraging half-life extension technologies for optimized dosing, though specifics for DMR-003 remain undisclosed.[5][7][9]

Targets

CALR mutant (Calreticulin Mutant Protein)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on DMR-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMR-003.

Explore the full profile